KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Neogenomics (NEO) EBT (2016 - 2026)

Neogenomics filings provide 17 years of EBT readings, the most recent being -$17.6 million for Q1 2026.

  • On a quarterly basis, EBT rose 31.49% to -$17.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$102.2 million, a 29.93% decrease, with the full-year FY2025 number at -$110.3 million, down 36.68% from a year prior.
  • EBT hit -$17.6 million in Q1 2026 for Neogenomics, down from -$12.4 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$12.4 million in Q4 2025 to a low of -$53.2 million in Q1 2022.
  • Median EBT over the past 5 years was -$25.7 million (2025), compared with a mean of -$27.4 million.
  • Biggest five-year swings in EBT: plummeted 155.88% in 2022 and later surged 45.86% in 2023.
  • Neogenomics' EBT stood at -$25.5 million in 2022, then surged by 40.11% to -$15.3 million in 2023, then decreased by 5.51% to -$16.1 million in 2024, then increased by 23.08% to -$12.4 million in 2025, then crashed by 41.69% to -$17.6 million in 2026.
  • The last three reported values for EBT were -$17.6 million (Q1 2026), -$12.4 million (Q4 2025), and -$26.4 million (Q3 2025) per Business Quant data.